Skip to content
Menu

Argus Research Upgrades Biogen to Buy, Announces $280 Price Target

Benzinga Newsdesk 3 weeks ago

Analyst RatingsNewsUpgradesPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Argus Research analyst Jasper Hellweg upgrades Biogen (NASDAQ:BIIB) from Hold to Buy and announces $280 price target.

Argus Research analyst Jasper Hellweg upgrades Biogen (NASDAQ:BIIB) from Hold to Buy and announces $280 price target.

Read at benzinga.com

← All stock news